VISCHER advised ImmunOs Therapeutics AG on all legal issues related to the transaction. ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based...
You must be a Standard 1 Year member to access this content.
VISCHER advised Haya Therapeutics SA on the Swiss legal aspects of the transaction. Cooley acted as lead counsel in this transaction. HAYA Therapeutics SA, a Swiss...
You must be a Standard 1 Year member to access this content.
VISCHER advised narrowin GmbH on all aspects on this transaction. The German energy supplier EnBW enters into a partnership with narrowin GmbH, a Swiss cybersecurity start-up....
You must be a Standard 1 Year member to access this content.
VISCHER advised EraCal on all legal issues related to the transaction. EraCal Therapeutics has signed a collaboration and license agreement with Danish pharma producer Novo Nordisk....
You must be a Standard 1 Year member to access this content.
VISCHER advised LASCCO SA on all legal issues related to the license agreement. LASCCO SA, a biomedical-technology company, and Abionic SA, a nanotechnology company, both based...
You must be a Standard 1 Year member to access this content.
VISCHER advises Epiterna with Prima Materia investment. Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro...
You must be a Standard 1 Year member to access this content.
VISCHER advised Medartis on the deal. Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private...
You must be a Standard 1 Year member to access this content.
Vischer advised Resistell AG on the deal. Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another...
You must be a Standard 1 Year member to access this content.
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Versantis with Mark Fitzpatrick as CEO, Vincent Forster as CSO and Meriam Kabbaj as COO. Goodwin advised the sellers. Linklaters and Niederer Kraft...
You must be a Standard 1 Year member to access this content.
VISCHER advised Novaremed AG on the deal. Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience...
You must be a Standard 1 Year member to access this content.
Lenz & Staehelin advised co-lead investors Samsara Biocapital and Lightspeed Venture Partners as their Swiss counsel. VISCHER advised ImmunOs. Walder Wyss advises Gimv. ImmunOs Therapeutics AG,...
You must be a Standard 1 Year member to access this content.
